Group 1: Investor Relations Activities - The company conducted a series of investor relations activities from March 4 to May 30, 2025, including online meetings and on-site research, involving a total of 10 to 40 participants per event [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25]. Group 2: Business Development in High-Tech Fields - The company has strategically invested in high-tech and emerging technology sectors, focusing on AI, humanoid robots, and low-altitude economy, enhancing its service offerings in these areas [6][7]. - In the automotive sector, particularly in new energy vehicles, the company has established deep collaborations with numerous manufacturers, ensuring safety and reliability in vehicle testing [9][10]. Group 3: Digital Financial Technology - The company has developed a three-dimensional testing system for digital financial technology products, achieving national-level testing qualifications for client-side and embedded software [8]. - Recent acquisitions have strengthened the company's position in the cybersecurity assessment market, expanding its service capabilities across multiple regions [8]. Group 4: Semiconductor and Chip Industry - The company remains optimistic about the long-term potential of the semiconductor industry, actively pursuing transformation and investment in key areas such as FA and MA [11]. - The company has optimized its management team and is focusing on enhancing operational capabilities to adapt to market changes [11]. Group 5: Pharmaceutical and Medical Sector - The pharmaceutical sector has shown signs of recovery after a period of adjustment, with a focus on high-value areas and stable client relationships [12][13]. - The company has completed the construction of comprehensive testing capabilities for medical devices, ensuring steady growth in revenue and profit [12][13]. Group 6: Future Revenue and Profit Growth - The company has maintained a strategic focus on long-term growth despite economic challenges, implementing a "123 strategy" to enhance operational efficiency and market positioning [14][22]. - The company plans to optimize resource allocation to create a balanced portfolio of cash flow, high-growth, and future reserve businesses [14]. Group 7: Mergers and Acquisitions Strategy - The company is actively pursuing strategic mergers and acquisitions to enhance its international competitiveness, focusing on sectors such as consumer goods and transportation [15][18]. - Recent acquisitions include the purchase of ALS Group's subsidiary in China, aimed at expanding capabilities in geochemical testing [19][20]. Group 8: Shareholder Returns and Dividends - The company has implemented a cash dividend policy, distributing RMB 1 per 10 shares to shareholders, with a historical payout ratio of 64.01% over the past three years [21]. - The board is considering increasing mid-term cash dividends to enhance shareholder returns [21]. Group 9: Strategic Resilience Amid Uncertainty - The company is committed to maintaining strategic stability in the face of external uncertainties, focusing on lean management and operational excellence [22][23]. - Plans include the integration of AI technologies to improve efficiency and service quality across various business segments [23][24].

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of RMB 1 per 10 shares and no bonus shares, approved by the shareholders' meeting held on May 19, 2025 [1][2][3]. Summary by Sections Shareholders Meeting Approval - The profit distribution plan was approved during the 2024 annual shareholders' meeting, with a cash dividend of RMB 1 per 10 shares (including tax) and no bonus shares [1][2]. Profit Distribution Plan - The total share capital for the distribution is 1,672,828,214 shares after excluding 10,000,000 repurchased shares. The total cash dividend amount is calculated to be RMB 167,282,821.40 [4][8]. Dividend Payment Details - The cash dividends will be directly credited to shareholders' accounts on May 28, 2025, through their respective securities companies [7]. - Different tax rates apply for various categories of shareholders, with specific provisions for Hong Kong investors and domestic investors [4][8]. Record and Ex-Dividend Dates - The record date for the dividend distribution is set for May 27, 2025, and the ex-dividend date is May 28, 2025 [4][5]. Calculation of Dividend and Reference Price - The reference price for the ex-dividend will be adjusted based on the cash dividend distributed per share, calculated as RMB 0.0994057 per share [8].

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of RMB 1 per 10 shares and no bonus shares, approved by the shareholders' meeting held on May 19, 2025 [1][2]. Summary by Sections 1. Profit Distribution Plan - The profit distribution plan involves a cash dividend of RMB 1 per 10 shares (including tax) for all shareholders, with no bonus shares distributed [1][2]. - The total amount for distribution will not exceed the distributable profits as per the financial statements, and adjustments will be made if the total share capital changes before implementation [1][2]. 2. Key Dates - The record date for the profit distribution is set for May 27, 2025, and the ex-dividend date is May 28, 2025 [2]. 3. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their custodial securities companies on the ex-dividend date [3]. 4. Calculation of Dividend - The actual cash dividend amount is calculated based on the total share capital minus repurchased shares, resulting in a cash dividend of approximately RMB 0.994057 per 10 shares [4]. - The reference price for the ex-dividend will be adjusted based on the cash dividend amount and the total share capital on the record date [4]. 5. Consultation Information - The company provides contact details for inquiries regarding the profit distribution plan, including a contact person and phone numbers [3].

证券代码：300012 证券简称：华测检测 公告编号：2025-028 华测检测认证集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华测检测认证集团股份有限公司（以下简称"公司"）2024 年年度权益分 派方案已获 2025 年 5 月 19 日召开的 2024 年度股东大会审议通过，现将权益分 派事宜公告如下： 一、股东大会审议通过权益分派方案情况 1、公司 2024 年度股东大会审议通过分配方案的具体内容：以公司实施利润 分配方案时股权登记日可参与利润分配的总股本为基数，向全体股东每 10 股派 发现金股利人民币 1 元（含税），送红股 0 股，以资本公积金向全体股东每 10 股转增 0 股。本次利润分配预案公布后至实施前，如公司参与分红总股本由于股 份回购、股权激励、员工持股计划等原因而发生变化时，按照分配比例不变的原 则，以未来实施本次分配预案时股权登记日参与分红的公司总股本为基数进行利 润分配，分红金额总额相应调整，公司预计分配总额不会超过财务报表上可供分 配利润。 现金（含税；扣税后，通过深股通持 ...

广东华商律师事务所 关于华测检测认证集团股份有限公司 2024 年度股东大会的 法律意见书 2025 年 5 月 中国深圳福田区深南大道 4011 号香港中旅大厦 第 21A-3 层、第 22A、23A、24A、25A、26A 层 广东华商律师事务所 关于华测检测认证集团股份有限公司 2024 年度股东大会的 法律意见书 致：华测检测认证集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）及中国证券监督管理委员会《上市公司 股东大会规则》（以下简称"《股东大会规则》"）等法律、法规及规范性文件的 规定，广东华商律师事务所（以下简称"本所"）接受华测检测认证集团股份有限 公司（以下简称"公司"）的委托，指派刘丽萍律师、张梅林律师出席了公司2024 年度股东大会（以下简称"本次股东大会"），就本次股东大会的有关问题，依法 出具本法律意见书。 本法律意见书仅就本次股东大会的召集和召开程序、出席本次股东大会人员的 资格、召集人资格、会议表决程序是否符合法律、法规及《公司章程》的规定以及 表决结果是否合法有效发表意见，并不对本次股东大会所审议的议 ...

证券代码：300012 证券简称：华测检测 公告编号：2025-027 华测检测认证集团股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决议案的情况； 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 1、会议召开时间： 5、主持人：董事长万峰先生。 6、公司董事、监事、高级管理人员出席了本次会议，见证律师列席了本次 会议。 7、本次股东大会的召开符合《公司法》《公司章程》等法律、法规及规范 性文件的规定。 （1）现场会议召开时间：2025 年 5 月 19 日（星期一）下午 14:30。 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的时间为 2025 年 5 月 19 日上午 9:15-9:25，9:30-11:30，下午 13:00-15：00；通过深圳证券 交易所互联网投票系统投票的具体时间为 2025 年 5 月 19 日 9:15-15:00 期间的 任意时间。 2、召开地点：深圳市宝安区新安街道留仙三路 4 号华测检测大楼一楼会议 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative return of over 20% within the next six months [6][17]. Core Views - The company has demonstrated stable revenue growth, with a total revenue of 6.084 billion yuan in 2024, reflecting an 8.55% year-on-year increase, and a net profit of 921 million yuan, up 1.19% year-on-year [1][2]. - The company is actively pursuing strategic mergers and acquisitions to enhance its international presence and core competitiveness, particularly in the green energy sector and electronic materials [4][6]. - The report highlights the company's strong performance in traditional sectors such as life sciences and industrial testing, with significant improvements in gross margins [3][4]. Financial Performance Summary - In 2024, the gross margin and net margin were 49.5% and 15.3%, respectively, showing a year-on-year increase of 1.41 percentage points and a decrease of 1.21 percentage points [2]. - For Q4 2024, the company achieved a revenue of 1.688 billion yuan, a year-on-year increase of 10.82%, and a net profit of 174 million yuan, up 2.96% year-on-year [2]. - The first quarter of 2025 saw revenues of 1.287 billion yuan, a 7.96% increase year-on-year, with a net profit of 136 million yuan, up 2.75% year-on-year [1][2]. Business Segment Analysis - In 2024, revenue from life sciences, industrial testing, consumer testing, trade assurance, and pharmaceuticals was 2.841 billion, 1.204 billion, 988 million, 764 million, and 287 million yuan, respectively, with year-on-year growth rates of 13.8%, 10.3%, 0.9%, 9.2%, and a decline of 14.7% [3]. - The environmental testing segment benefited from successful implementation of soil testing initiatives, leading to strong growth and improved gross margins [3]. - The industrial testing segment maintained stable operations in the maritime sector and expanded its global footprint through acquisitions, providing a strong growth impetus for 2025 [3][4]. Financial Forecast - The company expects net profits for 2025, 2026, and 2027 to be 1.013 billion, 1.154 billion, and 1.294 billion yuan, respectively, with year-on-year growth rates of 10%, 14%, and 12% [4][5]. - The report projects a revenue growth rate of 8.57% for 2025, with an estimated revenue of 6.605 billion yuan [5].

Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Views - The company achieved a revenue of 6.084 billion yuan in 2024, representing a year-on-year growth of 8.55%, while the net profit attributable to shareholders increased by 1.19% to 921 million yuan. The growth is attributed to the company's solid business advantages, accelerated development in strategic sectors, and improved operational efficiency [1][2] - In Q1 2025, the company reported a revenue of 1.287 billion yuan, up 7.96% year-on-year, and a net profit of 136 million yuan, reflecting a 2.75% increase [1] - The company is actively pursuing strategic acquisitions to enhance its international presence and operational capabilities, including acquisitions in the green energy and electronic materials sectors [2][3] Summary by Sections Financial Performance - In 2024, the company's revenue was 60.84 billion yuan, with a gross margin of approximately 49.47% and a net profit margin of 15.33% [1] - The company reported a non-recurring net profit of 860 million yuan, which is a 9.79% increase year-on-year [1] - The revenue breakdown by business segments for 2024 includes: Life Sciences (2.841 billion yuan, +13.75%), Industrial Testing (1.204 billion yuan, +10.32%), Consumer Testing (988 million yuan, +0.88%), Trade Assurance (764 million yuan, +9.19%), and Medical Services (287 million yuan, -14.71%) [2] Strategic Initiatives - The company is focusing on enhancing its core business through digital transformation and operational efficiency improvements [3] - Recent strategic acquisitions include a 51% stake in Changzhou Microtech and a 70% stake in Changzhou Honghai, aimed at strengthening its capabilities in electronic materials and PCB testing [2][3] Future Outlook - The profit forecast for 2025-2027 is adjusted to 1 billion yuan, 1.101 billion yuan, and 1.227 billion yuan respectively, with corresponding P/E ratios of 19, 17, and 16 [3][4] - The company plans to distribute a cash dividend of 1.67 billion yuan in 2024, which is about 21.26% of the net profit attributable to shareholders [3]

Core Insights - The company reported a revenue of 6.084 billion yuan for 2024, representing a year-on-year growth of 8.55% [1] - The net profit attributable to shareholders was 921 million yuan, with a year-on-year increase of 1.19% [1] - The company achieved a non-dedicated net profit of 860 million yuan, reflecting a year-on-year growth of 9.79% [1] Revenue Breakdown - The revenue from the life sciences segment was 2.841 billion yuan, growing by 13.75% year-on-year [1] - The industrial testing segment generated 1.204 billion yuan, with a year-on-year increase of 10.32% [1] - The consumer products segment achieved 988 million yuan, showing a slight growth of 0.88% year-on-year [1] - The trade assurance segment reported 764 million yuan, with a year-on-year growth of 9.19% [1] - The pharmaceutical and medical testing segment faced a decline, generating 287 million yuan, down 14.71% year-on-year [1] Profitability Metrics - The company's gross margin was 49.47%, reflecting a slight increase of 1.41 percentage points year-on-year [2] - The net profit margin was 15.33%, showing a slight decline of 1.21 percentage points year-on-year [2] - The gross margins for different segments were as follows: life sciences at 50.42%, industrial testing at 45.25%, consumer products at 43.53%, trade assurance at 71.21%, and pharmaceutical and medical services at 20.43% [2] Future Outlook - The company is expected to achieve revenues of 6.965 billion yuan, 8.124 billion yuan, and 9.22 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of approximately 14%, 17%, and 14% [3] - The net profit attributable to shareholders is projected to be 1.093 billion yuan, 1.275 billion yuan, and 1.479 billion yuan for the same years, with growth rates of about 19%, 17%, and 16% [3] - The company maintains a strong competitive advantage in traditional sectors and is expected to drive business growth through proactive innovation [3]

Investment Rating - The report maintains an "Accumulate" rating for the company [1][8] Core Views - The company has demonstrated steady revenue growth with a year-on-year increase in gross margin [1][7] - In 2024, the company achieved total operating revenue of 6.084 billion and net profit attributable to shareholders of 0.921 billion, representing year-on-year growth of 8.55% and 1.19% respectively [3][4] - The company is focusing on consolidating its advantages in traditional sectors while expanding into strategic areas such as life sciences, industrial testing, and consumer product testing [4][5] Summary by Sections Financial Performance - In 2024, the company reported total operating revenue of 60.84 billion and net profit attributable to shareholders of 9.21 billion, with a year-on-year growth of 8.55% and 1.19% respectively [3] - For Q1 2025, the company achieved total operating revenue of 12.87 billion and net profit of 1.36 billion, reflecting year-on-year growth of 7.96% and 2.75% respectively [3] Business Segments - The life sciences segment generated revenue of 28.41 billion, up 13.75% year-on-year, while the industrial testing segment saw revenue of 12.04 billion, increasing by 10.32% [4] - The consumer product testing segment reported a modest growth of 0.88%, with revenue reaching 9.88 billion [4] - The trade assurance segment achieved revenue of 7.64 billion, up 9.19%, while the medical and health services segment faced a decline of 14.71%, generating 2.87 billion [4] Strategic Initiatives - The company is actively pursuing strategic acquisitions to enhance its global presence, including the acquisition of NAIAS in Greece to strengthen its maritime services [4][5] - The company has also acquired a 51% stake in Changzhou Microtech, a leading third-party testing agency in the electronic materials and PCB industry, to boost its influence in this sector [5] Profitability and Forecast - The overall gross margin for 2024 was reported at 49.47%, an increase of 1.41 percentage points year-on-year [7] - The report forecasts operating revenues of 65.40 billion, 71.05 billion, and 78.34 billion for 2025, 2026, and 2027 respectively, with net profits of 10.34 billion, 11.81 billion, and 12.86 billion [6][8]